This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Homsi, J. Articles by Davis, M. Search for Related Content PubMed PubMed Citation Articles by Homsi, J. Articles by Davis, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Cancer Cold and Cough Medicines Cough Hazardous Substances DB HYDROCODONE Social Bookmarking                         What's this?

Hydrocodone for cough in advanced cancer

Harry R. Horvitz Center for Palliative Medicine (a World Health Organization Demonstration Project), The Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio

Declan Walsh, MSc, FACP

Harry R. Horvitz Center for Palliative Medicine, The Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio

Kristine A. Nelson, MD

Harry R. Horvitz Center for Palliative Medicine, The Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio

Susan B. LeGrand, MD

Harry R. Horvitz Center for Palliative Medicine, The Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio

Mellar Davis, MD

Harry R. Horvitz Center for Palliative Medicine, The Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio

Cough is a common symptom in advanced cancer. Hydrocodone is the antitussive of choice in our palliative medicine inpatient unit. We reviewed the pharmacy records for the use of hydrocodone for all cancer admissions to our unit from May 1996 to December 1998. Median treatment duration with hydrocodone was three days (range 1-18). Median maximum daily dose was 15 mg (range 5-100), and median total dose during the hospital stay was 32 mg (range 5-455). Lung cancer as a primary cancer site was strongly related to the use of hydrocodone. The highest median duration of treatment (five days) was for esophageal cancer and the highest median maximum daily dose (35 mg) and total dose (75 mg) were for treating kidney cancer. This retrospective review provides information regarding the use of hydrocodone on the palliative medicine unit of the Cleveland Clinic Foundation. Controlled trials are needed to evaluate the efficacy and safety of hydrocodone for cough in advanced cancer.

American Journal of Hospice and Palliative Medicine®, Vol. 17, No. 5, 342-346 (2000)
DOI: 10.1177/104990910001700512


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D Stolz, P N Chhajed, J D Leuppi, M Brutsche, E Pflimlin, and M Tamm Cough suppression during flexible bronchoscopy using combined sedation with midazolam and hydrocodone: a randomised, double blind, placebo controlled trial Thorax, September 1, 2004; 59(9): 773 - 776. [Abstract] [Full Text] [PDF]

				S. B. LeGrand, D. Walsh, K. A. Nelson, and M. P. Davis A syllabus for fellowship education in palliative medicine American Journal of Hospice and Palliative Medicine, July 1, 2003; 20(4): 279 - 289. [Abstract] [PDF]